U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Borderline Fallopian Tube Endometrioid Tumor

MedGen UID:
307296
•Concept ID:
C1511254
•
Neoplastic Process
Synonym: Borderline Fallopian Tube Endometrioid Neoplasm

Definition

A neoplasm of low malignant potential arising from the fallopian tube. It is characterized by the presence of glandular or cystic spaces which contain atypical glandular epithelial cells resembling endometrial cells. There is no evidence of stromal invasion. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVBorderline Fallopian Tube Endometrioid Tumor

Professional guidelines

PubMed

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS
Gynecol Oncol 2017 Apr;145(1):15-20. Epub 2017 Feb 21 doi: 10.1016/j.ygyno.2017.02.023. PMID: 28238354Free PMC Article

Recent clinical studies

Etiology

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Atypical Endometriosis: Comprehensive Characterization of Clinicopathologic, Immunohistochemical, and Molecular Features.
Wepy C, Nucci MR, Parra-Herran C
Int J Gynecol Pathol 2024 Jan 1;43(1):70-77. Epub 2023 Mar 13 doi: 10.1097/PGP.0000000000000952. PMID: 37043650
New insights in the pathophysiology of ovarian cancer and implications for screening and prevention.
Nezhat FR, Apostol R, Nezhat C, Pejovic T
Am J Obstet Gynecol 2015 Sep;213(3):262-7. Epub 2015 Mar 25 doi: 10.1016/j.ajog.2015.03.044. PMID: 25818671
Recent concepts of ovarian carcinogenesis: type I and type II.
Koshiyama M, Matsumura N, Konishi I
Biomed Res Int 2014;2014:934261. Epub 2014 Apr 23 doi: 10.1155/2014/934261. PMID: 24868556Free PMC Article
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.
Kurman RJ, Shih IeM
Am J Surg Pathol 2010 Mar;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79. PMID: 20154587Free PMC Article

Diagnosis

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Atypical Endometriosis: Comprehensive Characterization of Clinicopathologic, Immunohistochemical, and Molecular Features.
Wepy C, Nucci MR, Parra-Herran C
Int J Gynecol Pathol 2024 Jan 1;43(1):70-77. Epub 2023 Mar 13 doi: 10.1097/PGP.0000000000000952. PMID: 37043650
WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
Rajendran S, McCluggage WG
Int J Gynecol Pathol 2022 Mar 1;41(2):191-202. doi: 10.1097/PGP.0000000000000788. PMID: 33782345
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. PMID: 33545690
Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation.
Taylor EC, Irshaid L, Mathur M
Radiographics 2021 Jan-Feb;41(1):289-315. Epub 2020 Nov 13 doi: 10.1148/rg.2021200086. PMID: 33186060

Therapy

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS
Gynecol Oncol 2017 Apr;145(1):15-20. Epub 2017 Feb 21 doi: 10.1016/j.ygyno.2017.02.023. PMID: 28238354Free PMC Article
Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E
Acta Oncol 2016 Nov;55(11):1281-1284. Epub 2016 May 5 doi: 10.1080/0284186X.2016.1175660. PMID: 27148621
Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial.
Terada KY, Ahn HJ, Kessel B
J Gynecol Oncol 2016 May;27(3):e25. doi: 10.3802/jgo.2016.27.e25. PMID: 27029746Free PMC Article
Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N, Abubaker K, Findlay J, Quinn M
J Cell Biochem 2013 Jan;114(1):21-34. doi: 10.1002/jcb.24317. PMID: 22887554
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
Kurman RJ, Shih IeM
Int J Gynecol Pathol 2008 Apr;27(2):151-60. doi: 10.1097/PGP.0b013e318161e4f5. PMID: 18317228Free PMC Article

Prognosis

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Primary tumor types and origins in positive abdominopelvic washing cytology, a single institution experience.
Hou Y, Bruehl FK, McHugh KE, Reynolds JP
J Am Soc Cytopathol 2020 Mar-Apr;9(2):89-94. Epub 2019 Oct 14 doi: 10.1016/j.jasc.2019.10.001. PMID: 31734259
The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications.
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J
Arch Gynecol Obstet 2016 Apr;293(4):695-700. Epub 2016 Feb 19 doi: 10.1007/s00404-016-4035-8. PMID: 26894303
Recent concepts of ovarian carcinogenesis: type I and type II.
Koshiyama M, Matsumura N, Konishi I
Biomed Res Int 2014;2014:934261. Epub 2014 Apr 23 doi: 10.1155/2014/934261. PMID: 24868556Free PMC Article
Precursors and pathogenesis of ovarian carcinoma.
Lim D, Oliva E
Pathology 2013 Apr;45(3):229-42. doi: 10.1097/PAT.0b013e32835f2264. PMID: 23478230

Clinical prediction guides

Rare non-serous fallopian tube cancers: institutional experience and literature review.
Sumtsov D, Sumtsov G, Hyriavenko N, Lyndin M, Sikora K, Kalashnik N, Smiian S, Gladchuk I
Wien Med Wochenschr 2024 Jun;174(9-10):199-207. Epub 2023 Nov 28 doi: 10.1007/s10354-023-01027-3. PMID: 38015299
Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.
Richardson MT, Recouvreux MS, Karlan BY, Walts AE, Orsulic S
Cells 2022 Dec 11;11(24) doi: 10.3390/cells11244009. PMID: 36552773Free PMC Article
Differential epithelial and stromal LGR5 expression in ovarian carcinogenesis.
Kim H, Lee DH, Park E, Myung JK, Park JH, Kim DI, Kim SI, Lee M, Kim Y, Park CM, Hyun CL, Maeng YH, Lee C, Jang B
Sci Rep 2022 Jul 1;12(1):11200. doi: 10.1038/s41598-022-15234-2. PMID: 35778589Free PMC Article
WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms.
Rajendran S, McCluggage WG
Int J Gynecol Pathol 2022 Mar 1;41(2):191-202. doi: 10.1097/PGP.0000000000000788. PMID: 33782345
Napsin A is a specific marker for ovarian clear cell adenocarcinoma.
Yamashita Y, Nagasaka T, Naiki-Ito A, Sato S, Suzuki S, Toyokuni S, Ito M, Takahashi S
Mod Pathol 2015 Jan;28(1):111-7. Epub 2014 Apr 11 doi: 10.1038/modpathol.2014.61. PMID: 24721826

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...